Advancing Precision Medicine

What Advancing Precision Medicine does

Advancing Precision Medicine is a privately held, for-profit company headquartered in Fishers, Indiana, founded in 2024. According to its firmographic profile, the company's stated focus areas are precision medicine, clinical research, diagnostics, biomarkers, and healthcare development. The entity operates with a micro-team of 1-10 employees and has no publicly disclosed subsidiaries, investor backing, or parent organization.

There is no meaningful information available about the company's products, services, or underlying technology. Its website at advancingprecisionmedicine.com currently displays only a verification loading page ("One moment, please..."), exposing no product descriptions, platform architecture, technical components, or feature disclosures. The company has no documented patents, trademarks, certifications, partnerships, customer relationships, or named executives in the available data, and no revenue, pricing, or go-to-market mechanics are disclosed. The inputs collectively indicate an early-stage, pre-commercial entity with minimal public footprint and no verifiable operational activity beyond its registration and stated domain focus.

Name

Advancing Precision Medicine

Website

https://advancingprecisionmedicine.com

Company type

Private

Founded year

2024

Headcount range

1–10 employees

Short description

Advancing Precision Medicine is a privately held, 2024-founded micro-company based in Fishers, Indiana, self-described as focused on precision medicine, clinical research, diagnostics, biomarkers, and healthcare development, with 1-10 employees and no disclosed commercial activity.

Ownership category

akta.pro rank

Product category

Precision Medicine Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

Keywords

• Precision medicine
• Clinical research services
• Biomarker diagnostics
• Healthcare development
• Medical research services

Headquarters

HQ city

Fishers

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

Advancing Precision Medicine is a small private company focused on precision medicine, clinical research, diagnostics, biomarker analysis, and healthcare development. No specific, named products or services are documented in the available source material because the company's website was inaccessible (displaying only a verification loading page).

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Personalis: Personalis is a precision oncology company focused on genomic profiling and biomarker-driven clinical research. It is comparable to the anchor company through its focus on sequencing-based precision medicine and biomarker development.
• Guardant Health: Guardant Health develops liquid biopsy and precision oncology diagnostics. Its focus on biomarker-driven diagnostics and clinical research aligns closely with the precision medicine and biomarker development scope of the subject company.
• Tempus Labs: Tempus is a leading precision medicine company that combines clinical research, diagnostics, and biomarker analytics using multi-modal data. It directly parallels Advancing Precision Medicine's stated focus on precision medicine, clinical research, diagnostics, and biomarker development.
• Foundation Medicine: Foundation Medicine is a genomic profiling and precision medicine company specializing in molecular diagnostics for cancer. It is a direct comparable in genomic profiling and precision diagnostics — a core area within the anchor company's stated focus.
• Caris Life Sciences: Caris Life Sciences provides molecular profiling, biomarker discovery, and precision medicine services for oncology. It overlaps directly with the anchor company on multi-omics profiling, biomarker development, and clinical research.

Broad incumbents

• Natera: Natera is a clinical genomics company offering cell-free DNA and molecular diagnostic tests. It is comparable through its use of biomarker-based diagnostics and clinical research partnerships with biopharma companies.
• NeoGenomics: NeoGenomics is an established clinical laboratory and oncology diagnostics provider serving hospitals, pharma, and researchers. It represents a broad incumbent in the precision diagnostics and clinical research space relevant to the anchor company.
• Veracyte: Veracyte develops genomic diagnostics for oncology and other diseases, combining biomarker discovery with clinical testing. Its broader, established presence makes it a relevant incumbent comparable for the anchor company's precision medicine focus.
• Exact Sciences: Exact Sciences develops diagnostic screening and precision medicine products, including biomarker-based tests. Its scale and biomarker-driven diagnostics make it a relevant broad incumbent peer for the subject company.

Emerging players

• Helix: Helix is a population genomics and precision medicine company building a platform for genomic profiling and health-related applications. It is comparable as an emerging precision medicine platform player with focus on genomic data and clinical partnerships.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/advancing-precision-medicine

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advancing Precision Medicine